PUBLIC / مسلم PO Box 5674 Abu Dhabi, U.A.E

🕒 +971 2 4493333 🍈 +971 2 4449822 🌐 doh.gov.ae

تعميم رقم (Circular No (18) م

Date: 06/04/2020

To: All Healthcare Service Providers in the Emirate of Abu Dhabi

Subject: Epidemiological Surveillance & <u>Reporting of COVID-19 Cases</u>

Greetings,

We would like to extend you our greetings wishing you all the best and success.

With the increase in number of detected cases in different countries all over the world, and in order to utilize medical resources in a way that ensures sustainability of health services at all healthcare facilities in the Emirate of Abu Dhabi, all healthcare providers should implement the below:

 Strengthening epidemiological surveillance and enhancing prompt reporting to ADPHC all confirmed COVID-19 cases and Severe Acute Respiratory Infections (SARI) via ADPHC electronic notification system for infectious diseases (appendix-1 case definition).

Link: https://bpmweb.haad.ae/UserManagement/Login.aspx

 All cases of SARI or high-risk patients presenting with ILI symptoms who are vulnerable for developing complications must be tested for COVID-19 as priority. Other cases that are not at high risk should be tested only if there is no improvement in symptoms, and they should be advised home quarantine for 14 days or until they are symptoms free. السادة/ جميع مزودي الخدمات الصحية في إمارة أبوظبي المحترمين

<u>الموضوع: تعزيز الرقابة الوبائية والإبلاغ عن حالات</u> <u>فيروس كورونا المستجد</u>

تحية طيبة وبعد ...

نتقدم إليكم بخالص التحية والتقدير متمنين لكم دوام التوفيق والسداد.

مع تزايد الأعداد المكتشفة في دول العالم ولتحقيق الاستغلال الأمثل للموارد الطبية بما يضمن استدامة تقديم الخدمات الصحية في كافة المنشآت الصحية في إمارة أبوظبي، يتوجب على جميع مقدمي الخدمات الصحية تطبيق ما يلي:

 تعزيز المراقبة الوبائية وتعزيز الإبلاغ الفوري لمركز أبوظبي للصحة العامة لجميع حالات COVID-19 المؤكدة والالتهابات التنفسية الحادة الوخيمة (SARI) عبر نظام التبليغ الإلكتروني للأمراض المعدية (الملحق رقم-1 تعريف الحالة).

الرابط: https://bpmweb.haad.ae/UserManagement/Login.aspx

يجب فحص جميع حالات الالتهاب الرئوي الشديد (SARI) أو المرضى الذين تظهر عليهم أعراض تنفسية خفيفة ولكنهم من الفئة المعرضة لمضاعفات المرض كأولوية. كما يجب فحص الحالات الأخرى غير عالية الخطر في حالة عدم حدوث تحسن في الأعراض ويجب نصحهم بالحجر الصحي المنزلي لمدة 14 يوم أو حتى زوال الأعراض.







التاريخ: 2020/04/06





- مركز أبوظبي ABU DHABI PUBLIC HEALTH CENTRE
- بالنسبة للأشخاص المخالطين لحالات إيجابية مؤكدة ينصح ببقائهم في الحجر في المنزل لمدة 14 يوم كحد أدنى
 حتى لو كانت نتيجة الفحص الطبي سلبية
- يجب على المختبرات التي تجري اختبار COVID-19 أن تبلغ فوراً عن أي نتائج إيجابية إلى منشآت الرعاية الصحية المعنية بالإضافة لمشاركة النتيجة مع المعنيين في مركز عمليات دائرة الصحة ومركز أبوظبي للصحة العامة
- يجب أن تكون كل منشأة صحية مسؤولة عن التواصل مع المرضى وتنسيق الدخول إلى المستشفى للمرضى أو إدخالهم إلى المرافق المعتمدة للعزل الصحي (ملحق رقم-2) والاتصال بمركز عمليات دائرة الصحة إذا لم تكن الأسرة متوفرة في منشآتهم.
- يجب على جميع المنشآت الصحية تنفيذ التوصيات بشأن استخدام الأدوية لعلاج الحالات المصابة بفيروس COVID-19 والعلاج الوقائي (يجب تحديد شدة المرض) يرجى مراجعة المحلق رقم-3 حول بروتوكول العلاج.
- يجب الأخذ بعين الاعتبار فحص المخالطين للحالات المصابة من الأشخاص الأكثر عرضة لمضاعفات مرض كوفيد 19 وكذلك العاملين الصحيين الذين تعاملوا مع مرضى مصابين بدون أخذ الاحتياطات اللازمة.
- تنفيذ نقاط فرز ما قبل الدخول في جميع مداخل
 المنشآت الصحية بما في ذلك الرعاية العاجلة وأقسام
 الطوارئ والعيادات أو مراكز جراحة اليوم الواحد.
- يمكن إجراء عملية ما قبل الفرز من قبل العاملين في الرعاية الصحية (الممرضات والأطباء والمتدربين والأطباء المقيمين وطلاب الطب أو مزاولي المهن الصحية من غير هؤلاء) .يرجى الرجوع للملحق رقم-4 لمزيد من التفاصيل حول ما قبل الفرز.

شاكرين لكم حسن تعاونكم معنا ،،،

- As for contacts of positive confirmed cases, they are advised to stay at home quarantine for 14 days minimum even if the test result is negative.
- Laboratories conducting the COVID-19 testing must immediately report any positive results to the concerned healthcare facilities besides sharing the result with the concerned staff in the DoH Operations Center and Abu Dhabi Public Health Center.
- Each healthcare facility must be responsible for communicating with patients, coordinating their admission to the hospital, or admission to other healthcare facilities approved for isolation (appendix-2) and liaise with DOH Operations Center if beds are not available in their facility.
- All HCFs should implement the recommendations on the use of medications for COVID-19 treatment and prophylaxis (The severity of the disease must be determined). Please refer to appendix-3 on treatment protocol for COVID-19
- Close contacts of confirmed COVID-19 cases who are at higher risk of complications from COVID-19, as well as healthcare workers who managed infected patients without taking the necessary precautions, should be tested for COVID-19.
- Implement Pre –Triage Checkpoints at all HCF entrances including urgent care, emergency departments, clinics or day surgery centers.
- Pre-Triage can be performed by any health care professional (Nurses, physicians, interns, residents, medical students or allied health). Please refer to appendix-4 for more details about pre-triaging

Thanking you for your kind cooperation,,,







المرفقات:

- تعريف الحالة المحدث
 - 2. التعامل مع الحالات
 - 3. بروتوكول العلاج
- فرز الحالات ما قبل الدخول

"هذا التعميم للإجراءات التنظيمية وغير مخصص كمحتوى للنشر الإعلامي".

5.1

د. جمال محمد الكعبي وكيل دائرة الصحة بالإنابة



Appendices:

- 1. Updated case definition
- 2. Case management
- 3. Treatment protocol
- 4. Patient's pre-triaging

"This circular is designed for regulatory procedures and should not be used as content for media publication"



PO Box 5674 Abu Dhabi, U.A.E
+971 2 4493333 +971 2 4449822 doh.gov.ae



Appendix#1: Case Definition for suspected COVID-19 Case



Notes • with onset within the last 10 days • and requires hospitalization	Notes	
--	-------	--

This flow chart may change as further information emerges.









Term	Symptoms	Clinical Assessment/diagnosis
Asymptomatic	Patient has a positive confirmed laboratory COVID 19 test with no symptoms.	
Mild	 Patients with uncomplicated upper respiratory tract viral infection, may have non-specific symptoms such as: Fever < 38.5°C Fatigue, Cough (with or without sputum production) Anorexia, malaise, muscle pain Sore throat Nasal congestion Headache Rarely, patients may also present with GI symptoms of diarrhea, nausea and vomiting 	Stable Oxygen saturation exceeds 93% Respiratory rate is less than 30
Moderate	 Dyspnea and other non-specific symptoms: Fever < 38.5°C Fatigue, Cough (with or without sputum production) Anorexia, malaise, muscle pain Sore throat Nasal congestion Headache Rarely, patients may also present with GI symptoms of diarrhea, nausea and vomiting 	Signs of Pneumonia, lower respiratory symptoms
Severe	Patient with pneumonia & respiratory distress	patient with any one of the following criteria: -Respiratory distress (RR>30/min, adults) (RR >40/min, child < 5 yr) -O sat < 93% at rest -PaO2/FiO2 <300 mmhg -Lung infiltrate > 50% of the lung fields in 24-48 hr
Critical	 All mentioned above and complicated by: Persistent pain or pressure in the chest New confusion or inability to arouse Bluish lips or face 	Acute respiratory distress syndrome Sepsis Septic Shock 2 https://CoVID-19.uwmedicine.org/Pages/default.aspx



Risk Matrix for COVID-19

to support physicians in the decision making for admission priority and treatment for <u>confirmed</u> COVID-19 cases

Risk Category	Asymptomatic Positive COVID 19 test	Mild	Moderate	Severe	Critical
Patient with Risk	Hospital admission/ Institution with medical care	Hospital admission	Admit to Assigned hospital	Admit to Assigned hospital	Admit to Assigned hospital
No risk	Institution admission with medical care	Institution admission with medical care	Hospital admission	Hospital admission	Admit to assigned hospital

Definition of High risk:

- People aged 65 years and older
- People who live in a nursing home or long-term care facility
- Other high-risk conditions could include:
 - People with chronic lung disease or moderate to severe asthma
 - People who have serious heart conditions
 - People who are immunocompromised including cancer treatment
 - People of any age with severe obesity (body mass index [BMI] >40) or certain underlying medical conditions, particularly if not well controlled, such as those with diabetes, renal failure, or liver disease might also be at risk
- People who are pregnant should be monitored since they are known to be at risk with severe viral illness, however, to date data on COVID-19 has not shown increased risk

Many conditions can cause a person to be immunocompromised, including cancer treatment, smoking, bone marrow or organ transplantation, immune deficiencies, poorly controlled HIV or AIDS, and prolonged use of corticosteroids and other immune weakening medications





For more information you can visit the below website:

https://www.who.int/emergencies/diseases/novel-coronavirs-2019/situation-reports

Management of suspected or confirmed COVID-9 cases



.

Appendix 3

Protocol for Treatment and Monitoring of COVID-19 Cases:

** Baseline Labs for All patients :

- CBC, Lytes , Coagulation Profile , CRP, Ferritin, LFT's, Amylase, Lipase, then **to be repeated Q 3 days for the Treatment Duration**
- <u>G6PD baseline, blood glucose monitoring especially if diabetic (if on Chloroquine or Hydroxychloroquine)</u>
- ٠

Baseline ECG and consider repeat for patients suspected to have QTc prolongation (elderly, patients with electrolyte imbalances, history of arrhythmias, Taking other medications prolonging QTc

CONFIRMED CASES :

Baseline CHEST CT (If Symptomatic) or CXR (If Asymptomatic) for ALL CONFIRMED CASES to rule out Pneumonia

** Treatment Arm :

PLEASE CHOOSE 1 DRUG, EITHER HYDROXYCHLOROQUINE OR CHLOROQUINE (WHICHEVER IS AVAILABLE)

WHICHEVER IS AVAILABLEJ		
Without radiological evidence of pneumonia:		
- Hydroxychloroquine 200mg PO BID		
With radiological evidence of pneumonia:		
<u> </u>		
- Lopinivir-Ritonavir (200/50mg) 2 tablets PO BID		
- AND Chloroquine Phosphate 250mg PO BID		
- (OR Hydroxychloroquine 200mg BID)		
- Lopinavir-Ritonavir (200/50mg) 2 tablets PO BID		
- AND Chloroquine Phosphate 250mg PO BID		
(OR Hydroxychloroquine 200mg BID)		
- Lopinavir-Ritonavir (200/50mg) 2 tablets PO BID		
- AND Chloroquine Phosphate 250mg PO BID		
(OR Hydroxychloroquine 400mg BID on day 1, followed by 200mg		
BID from day 2)		

Symptomatic CLOSE CONTACTS OF ALL CONFIRMED CASES:

- Screen for COVID 19 PCR
- Treat With <u>Hydroxychloroquine 200mg PO BID for 7 days awaiting results</u>

IF COVID TURNS POSITIVE, Move to Above Treatment arm and modify treatment accordingly if needed

REST OF THE CONTACTS:

- Isolate and Monitor for symptoms .
- To screen for COVID-19 if develop any symptoms and treat if positive . Follow above treatment protocol







- Implement Pre –Triage Check points at all HCF entrances including Urgent care, emergency Departments and Clinics or Day surgery centers.
- Pre-Triage can be performed by any health care professional (Nurses, physicians, interns, residents, medical students or allied health)
- The check point goals is to keep patients with influenza like illness away from HCF and instruct them to self isolate till symptoms improves on the other hand capture those who have CoVID risk factors (Travel in the past 14 days or contact with confirmed CoVID case) and isolate then test them.
- All Emergency Departments and Urgent care centers need to designate Influenza Like illness (ILI) assessment area that separate these patients from patients presenting with other emergencies
- If ED or Urgent care centers space dose not allow them to segregate ILI then they need to build temporary appropriate temporary building (prefab, precast, steel structure, container home, portable cabin, etc..). See appendix for design

Appendix4/v1/042020



Pre-triage - design concept

- To be located outside hospital ED/ UCC
- Temporary building (prefab, precast, steel structure, container home, portable cabin, etc..)
- No waiting inside

مركـز أبـوظبــي | ABU DHABI PUBLIC للـصـحـة الـعـامـة | HEALTH CENTRE

- Two Clinical staff per room with full PPE
- Patients to be directed to ED if sick or to go home for home isolation if ILI till swab result is out or symptoms resolution.
- Disinfection between patients









Patient ED / UCC Flow Strategy







Risk Matrix for COVID-19

Developed in Abu Dhabi to support physicians in the decision making for admission priority and treatment for confirmed COVID-19 cases

Risk Category	Asymptomatic Positive COVID 19 test	Mild	Severe	Critical
Patient with Risk	Hospital admission/ Institution with medical care	secondary Hospital admission	Tertiary assigned hospital	Tertiary assigned hospital
No risk	Isolation/Institution with medical care	Isolation/Institution with medical care	Secondary hospital	Tertiary assigned hospital

Definition of High risk:

- People aged 65 years and older
- People who live in a nursing home or long-term care facility
- Other high-risk conditions could include:
 - People with chronic lung disease or moderate to severe asthma
 - People who have serious heart conditions
 - People who are immunocompromised including cancer treatment
 - People of any age with severe obesity (body mass index [BMI] >40) or certain underlying medical conditions, particularly if not well controlled, such as those with diabetes, renal failure, or liver disease might also be at risk
- People who are pregnant should be monitored since they are known to be at risk with severe viral illness, however, to date data on COVID-Appendix4/v1/042020
 19 has not shown increased risk

Many conditions can cause a person to be immunocompromised, including cancer treatment, smoking, bone marrow or organ transplantation, immune deficiencies, poorly controlled HIV or AIDS, and prolonged use of corticosteroids and other immune weakening medications





Clinical Assessment for patients suspect COVID-19

Term	Symptoms	Clinical Assessment/diagnosis
Asymptomatic	Patient has a positive confirmed laboratory COVID 19 test with no symptoms.	
Mild	 Patients with uncomplicated upper respiratory tract viral infection, may have non-specific symptoms such as: Fever < 38.5°C Fatigue, Cough (with or without sputum production) Anorexia, malaise, muscle pain Sore throat Nasal congestion Headache Rarely, patients may also present with GI symptoms of diarrhea, nausea and vomiting 	Stable Oxygen saturation exceeds 93% Respiratory rate is less than 30
Severe	 Dyspnea and other non-specific symptoms: Fever < 38.5°C Fatigue, Cough (with or without sputum production) Anorexia, malaise, muscle pain Sore throat Nasal congestion Headache Rarely, patients may also present with GI symptoms of diarrhea, nausea and vomiting 	Signs of Pneumonia, lower respiratory symptoms
Critical	 All mentioned above and complicated by: Persistent pain or pressure in the chest New confusion or inability to arouse Bluish lips or face 	Acute respiratory distress syndrome Sepsis Septic Shock





CoVID-19 Algorithm in Ambulatory Services







CoVID-19 Algorithm in Ambulatory Services







The following apply on CoVID-19 patients admitted in hospital

- Visiting patients should be discouraged and replaced by phone or virtual means
- On admission, the hospital should initiate credentials for tele-visit to which allow remote, virtual visit to patient rather than physical visit and exposure to infection

Less recommended :

• Limit visit to the patient to only one visitor at a time to limit their exposure.

Appendix4/v1/042020